abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
Cost of Revenue
$3.12M
Quarterly · Period ending: · USD
HQL Cost of Revenue
Latest reported$3.12Mperiod ending
Latest reported$3.12Mperiod ending
HQL Quarterly Cost of Revenue ($800.00K → $3.12M)
Quarterly cost of revenue
High-resolution chart · PNG
HQL cost of revenue history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 3,116,770 | |
| 2,443,873 | |
| 2,526,817 | |
| 2,825,673 | |
| 2,531,579 | |
| 2,590,370 | |
| 2,653,677 | |
| 2,643,159 | |
| 2,905,791 | |
| 3,104,893 | |
| 2,971,143 | |
| 2,721,309 | |
| 2,484,709 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 4,820,280 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 2,480,000 | |
| 1,510,000 | |
| 1,510,000 | |
| 1,495,000 | |
| 1,495,000 | |
| 1,425,000 | |
| 1,425,000 | |
| 1,880,000 | |
| 1,880,000 | |
| 1,810,000 | |
| 1,810,000 | |
| 1,465,000 | |
| 1,465,000 | |
| 1,405,000 | |
| 1,405,000 | |
| 1,390,000 | |
| 1,390,000 | |
| 1,220,000 | |
| 1,220,000 | |
| 1,430,000 | |
| 1,430,000 | |
| 1,630,000 | |
| 1,630,000 | |
| 820,000 | |
| 820,000 | |
| 815,000 | |
| 815,000 | |
| 800,000 | |
| 800,000 |